265 related articles for article (PubMed ID: 19728856)
21. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
23. Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers.
Li Z; Guo S; Yao F; Zhang Y; Li T
J Diabetes Complications; 2013; 27(4):380-2. PubMed ID: 23357650
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
25. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
26. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
27. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
28. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of proteolytic activity imbalance in breast cancer diagnosis.
Swellam M; Soliman HA; Abdelmaksoud MD; Nageeb AM; El Arab LR; Boshnak H
Cancer Biomark; 2014; 14(6):409-17. PubMed ID: 25335732
[TBL] [Abstract][Full Text] [Related]
30. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
31. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
32. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Nielsen HJ; Christensen IJ; Brünner N
Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
[TBL] [Abstract][Full Text] [Related]
33. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
34. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
35. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
36. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.
Huang X; Lan Y; Li E; Li J; Deng Q; Deng X
J Int Med Res; 2021 May; 49(5):3000605211012570. PubMed ID: 33942633
[TBL] [Abstract][Full Text] [Related]
38. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
39. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
40. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
Palus M; Zampachová E; Elsterová J; Růžek D
J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
